ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that it will host a conference call at 8:00 am ET on Friday, March 30, 2012 to discuss the two releases issued by the Company earlier today: The announcement of positive results in the trastuzumab emtansine (T-DM1) EMILIA Phase III trial; and The announcement of initiation of Phase II evaluation of IMGN901. To access the live call by phone, dial 913-312-0982. Passcode is 8250254. The call also may be accessed through the Investor Information section of the Company's website, www.immunogen.com . Following the live webcast, a replay of the call will be available at the same location through April 6, 2012 . About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare , Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech , a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com . For Investors: ImmunoGen, Inc. Carol Hausner , 781-895-0600 Executive Director, Investor Relations and Corporate Communications [email protected] or For Media: The Yates Network Barbara Yates , 781-258-6153 Source: ImmunoGen, Inc. News Provided by Acquire Media

The release as fetched from its publisher. abbvie.com ↗